lifitegrast
CHEBI:CHEBI_133023
Definition
An N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of N-[2-(1-benzofuran-6-carbonyl)]-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid with the amino group of 3-(methanesulfonyl)-L-phenylalanine. Used for treatment of keratoconjunctivitis sicca (dry eye syndrome).
Chemical Information
- Molecular Formula
- C29H24Cl2N2O7S
- Molecular Mass
- 615.483
- Charge
- 0
- SMILES
- C12=C(C=C(C=C1)C(N3CC=4C(CC3)=C(C(=C(C4)Cl)C(N[C@@H](CC5=CC=CC(=C5)S(C)(=O)=O)C(=O)O)=O)Cl)=O)OC=C2
- InChI
- InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
- InChIKey
- JFOZKMSJYSPYLN-QHCPKHFHSA-N
Alternative Names
- lifitegrast
- N-[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carbonyl]-3-(methanesulfonyl)-L-phenylalanine
- SAR 1118
- SAR-1118
- SAR1118
- Xiidra
Drug Classification
-
sulfoneView Class →
CHEBI:35850
-
isoquinolinesView Class →
CHEBI:24922
-
1-benzofuransView Class →
CHEBI:38830
-
N-acyl-L-alpha-amino acidView Class →
CHEBI:48927
-
L-phenylalanine derivativeView Class →
CHEBI:84144
-
t99529
-
t99637
Important Medical Information
⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.
- Always consult with a healthcare professional before starting, stopping, or modifying any medication.
- Side effects may vary and this list may not be comprehensive.
- Drug interactions may occur with other medications.
Additional Identifiers
- core#notation
- CHEBI:133023
- DRON_00010000
- 1801820
- oboInOwl#hasDbXref
- Wikipedia:Lifitegrast
Additional References
🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.
Additional Attributes
- core#notation
- CHEBI:133023
- rxcui
- 1801840
- active_ingredient_strength
- 35 kg/35kg
- package_marketing_start_date
- 15-AUG-17
- route
- OPHTHALMIC
- manufacturer_name
- Bausch & Lomb Incorporated
- active_ingredient_name
- LIFITEGRAST
- package_ndc
- 64552-4089-1
- package_description
- 25 kg in 1 CARTON (64552-4089-1)
- spl_id
- c3260964-0f33-58d8-e053-2a95a90aadaf
- unii
- 038E5L962W
- spl_set_id
- 8589d376-ac10-4ddb-9c53-2e0c8d5675c4
- nui
- N0000192700
- pharm_class_epc
- Lymphocyte Function-Associated Antigen-1 Antagonist [EPC]
- pharm_class
- Lymphocyte Function-Associated Antigen-1 Antagonists [MoA]
- pharm_class_moa
- Lymphocyte Function-Associated Antigen-1 Antagonists [MoA]
- 22-rdf-syntax-ns#type
- http://www.w3.org/2002/07/owl#Class
- oboInOwl#hasOBONamespace
- chebi_ontology
- DRON_00010000
- 1801820
- oboInOwl#hasDbXref
- Wikipedia:Lifitegrast
- oboInOwl#id
- CHEBI:133023
- brand_name
- Lifitegrast
- brand_name_base
- Lifitegrast
- product_type
- BULK INGREDIENT
- marketing_category
- BULK INGREDIENT
- listing_expiration_date
- 20241231
- dosage_form
- FOR SOLUTION
- marketing_start_date
- 20190829
- labeler_name
- Bausch & Lomb Incorporated
- generic_name
- Lifitegrast Type II
- product_ndc
- 64552-4089
- application_number
- ANDA215063
- RO_0000087
- http://purl.obolibrary.org/obo/CHEBI_35472
- oboInOwl#inSubset
- http://purl.obolibrary.org/obo/chebi#3_STAR
- rdf-schema#domain
- https://w3id.org/def/predibionto#has_side_effect2066
- owl#annotatedSource
- t100703
- has_treatment
- http://purl.obolibrary.org/obo/DOID_12895
- owl#someValuesFrom
- t3038316